menu
    • menu

    Company profile for Duality Biologics

    NEW Drugs in Dev: 11
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases. Leveraging on the decades of learning, we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. These include DITAC (Duality Immune Toxin Antibody Conjuga...
    DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases. Leveraging on the decades of learning, we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. These include DITAC (Duality Immune Toxin Antibody Conjugate) with significantly improved therapeutic window and DIMAC (Duality Immune Modulating Antibody Conjugate) with superior efficacy than traditional biologics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Duality BiologicsChina Flag
    Country
    Country
    China
    Address
    Address
    Unit 1105-1106, No 868 YingHua Road, Pudong New District, Shanghai
    Telephone
    Telephone
    021-2601 8730
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://dualitybiologics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioNTech, DualityBio Tout ADC Efficacy in Endometrial Cancer
    BioNTech, DualityBio Tout ADC Efficacy in Endometrial Cancer

    13 Apr 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/biontech-dualitybio-tout-clinically-meaningful-efficacy-for-adc-in-mid-stage-endometrial-cancer-trial

    BIOSPACE
    13 Apr 2026
    Share Share
    BioNtech And Dualitybio's Trastuzumab Pamirtecan Shows Efficacy
    BioNtech And Dualitybio's Trastuzumab Pamirtecan Shows Efficacy

    11 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/11/3272109/0/en/BioNTech-and-DualityBio-s-Antibody-Drug-Conjugate-Trastuzumab-Pamirtecan-Demonstrated-Clinically-Meaningful-Efficacy-in-Patients-with-HER2-Expressing-Recurrent-Endometrial-Cancer.html

    GLOBENEWSWIRE
    11 Apr 2026
    Share Share
    NMPA Accepts BLA for Trastuzumab Pamirtecan in Breast Cancer
    NMPA Accepts BLA for Trastuzumab Pamirtecan in Breast Cancer

    09 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dualitybio-announces-china-nmpa-acceptance-of-biologics-license-application-seeking-approval-for-trastuzumab-pamirtecan-for-the-treatment-of-unresectable-or-metastatic-her2-positive-adult-breast-cancer-302738250.html

    PR NEWSWIRE
    09 Apr 2026
    Share Share
    BioNTech, DualityBio Ph 3 ADC Meets Goal in HER2+ Breast Cancer
    BioNTech, DualityBio Ph 3 ADC Meets Goal in HER2+ Breast Cancer

    06 Sep 2025

    // PRESS RELEASE

    https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate

    PRESS RELEASE
    06 Sep 2025
    Share Share
    ADC Candidates' Preliminary Data Presented at 2025 ASCO Meeting
    ADC Candidates' Preliminary Data Presented at 2025 ASCO Meeting

    04 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/preliminary-data-from-two-clinical-trials-with-adc-candidates-were-presented-orally-at-the-2025-asco-annual-meeting-302473942.html

    PR NEWSWIRE
    04 Jun 2025
    Share Share
    FDA Clears NDA Application for Drug AVZO-1418/DB-1418
    FDA Clears NDA Application for Drug AVZO-1418/DB-1418

    22 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-clearance-of-investigational-new-drug-application-received-for-novel-egfrher3-bispecific-antibody-drug-conjugate-avzo-1418db-1418-302463934.html

    PR NEWSWIRE
    22 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search